Information about the interruption in manufacturing and supply chain with Norcuron 4 mg powder for solution for injection or infusion (vecuronium bromide)
03.03.2014
The marketing authorisation holder for Norcuron 4 mg powder for solution for injection or infusion (vecuronium bromide), Merck Sharp & Dohme d.o.o., has informed the Agency for Medicinal Products and Medical Devices (HALMED) on the interruption in manufacturing and supply chain of the Croatian market with this medicine and revocation of the marketing authorisation.
The decision on interruption in manufacturing and supply chain with this medicine has been taken due to commercial reasons and it is not linked to quality, safety or efficacy of the medicinal product. There is no other medicine with the same active substance on the Croatian market.
For the treatment of patients in Croatia, another medicine from the same therapeutic group, with another active substance is available.
